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Abstract
Background: Nm23 protein is a metastasis suppressor protein, expressed in all tissues. Reduced
Nm23 expression is related to a high incidence of lymph node and distant metastasis and poor
prognosis in patients with cancers. The present study was done to analyze the expression of Nm23
using immunohistochemistry in non-neoplastic and neoplastic breast lesions.
Methods: Sections from 93 samples were studied and classified into non-proliferative breast lesion
(13), fibrodenoma (7), proliferative breast lesion (13), carcinoma in situ (20), invasive carcinoma
(23) and metastatic deposits in lymph nodes (17).
Results: Nm23 expression in these groups showed a progressive down regulation with increasing
neoplastic transformation. On comparing the various groups, nm23 expression was significantly
different between the various subgroups with greatest expression in non-proliferative lesions and
least in metastatic deposits (p < 0.050).
Conclusion: It is concluded that the modulation of nm23 in a spectrum of breast lesions can be
indicative of metastatic phenotype and help to predict the aggressiveness of disease.
Introduction
Breast cancer is the most common cancer in women of the
developed countries with a persistently rising incidence
[1]. Extensive research on diagnostic and therapeutic
aspects has contributed little to decrease the mortality.
This may be attributed to a relative lack of understanding
of the natural history of disease and heterogeneity of pre
invasive lesions [2].
Various biological makers known to be indicators of prog-
nosis in breast cancer include growth factor receptors, oes-
trogen receptors, p53, bcl2, Her-2/neu oncogenes and
proliferation indices like Ki67. But the most important
prognostic factor remains the axillary lymph node status
[3,4]. Majority of breast cancer patients succumb to meta-
static disease. The molecular basis of the metastatic dis-
ease is not known, but activation or inactivation of
multiple genes is involved in the various steps of tumor
progression [5].
Non metastatic (nm23) gene is the one possible candidate
that suppresses the metastatic phenotype [6]. It was first
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identified by Steeg et al [7] in murine melanoma cells and
inverse relationship between metastatic potential and
nm23 RNA protein was found in four different metastatic
models. Nm23 gene has been localized at chromosome
17q21 and two isoforms (nm23-H1 and nm23-H2) have
been identified. Each isoform encodes 17 KD protein hav-
ing non-specific nucleoside diphosphate kinase (NDPK)
activity [8]. Reduced expression of nm23 in breast, hepa-
tocellular and ovarian carcinoma correlates with
increased metastatic potential [9-11]. On the contrary, in
prostate and lung carcinomas, disease progression is asso-
ciated with increased nm23 gene expression [12,13].
Breast carcinogenesis is known to be a multistep process
and emerges through hyperplasia to atypical hyperplasia
and carcinoma in situ [14,15]. Loss of heterozygosity at
chromosome 16 and 17 has been observed in ductal car-
cinoma in situ (DCIS) and lobular carcinoma in situ
(LCIS) showing that these genetic abnormalities take
place before invasion[16].
The study has been designed to evaluate the expression of
nm23/NDPK in breast epithelial lesions that are pre-
sumed to represent steps in progression of breast carci-
noma.
Materials and methods
Formalin fixed paraffin-embedded sections of breast
lesions were retrieved from the archives of the Depart-
ment of Histopathology, PGIMER, Chandigarh. There
were 93 samples in total; which were classified by the cri-
teria of Dupont and Page[17,18] into six groups as: Non
proliferative breast disease (fibrocystic disease, apocrine
change and mild epithelial hyperplasia)-13 cases, fibroad-
enoma-7 cases, proliferative breast disease (moderate and
florid hyperplasia)-13 cases, atypical hyperplasia and car-
cinoma in situ (ductal and lobular)-20 cases, invasive car-
cinoma(ductal and lobular)-23 cases, and metastatic
deposits in lymph nodes-17 cases. None of these cases
had received prior chemotherapy.
For immunohistochemistry avidin-biotin method was
used. The antibody used was rabbit anti-human mono-
clonal antibody nm23 at 1:40 dilution (DAKO).
Quantification of immunostaining
The expression of the antigen was evaluated in a semi-
quantitative manner as previously described by Bankfalvi
et al [19]. Sections were scored based on two parameters:
(a) Percentage of positively stained cells; no staining-0,
<5% cells stained-1, 5–75% cells stained-2, >75% cells
stained-3 (b) Intensity of staining; absent -0 mild-1, mod-
erate-2, strong-3.
Multiplying the values of both parameters generated
immunoreactivity scores and this ranged from 0 to 9.
Statistical analysis
ANOVA test was applied to compare scores between the
groups.
Results
The results are summarized in table 1.
Nm23 expression in non-proliferative breast lesions
This group includes fibrocystic disease, apocrine change
and mild epithelial hyperplasia (13 cases). Nm23 was
strongly expressed in epithelial as well as stromal cells.
Homogeneous staining pattern was observed in cyto-
plasm of both epithelial and myoepithelial cells (Fig. 1).
Immunoreactivity score ranged from 4–9 (mean = 7.150,
SD = 2.190). Scores were statistically significanty higher
when compared with other groups (proliferative lesions p
< 0.050, carcinoma in situ p < 0.001, invasive carcinoma
p < 0.001 and lymph node metastasis p < 0.001).
Nm23 expression in fibroadenoma
Seven cases of fibroadenoma were studied. A homogene-
ous and strong nm23 expression approximating non-pro-
liferative lesions was observed in epithelial and stromal
cells (Fig. 2). Score ranged from 4–9 (mean = 7.860, SD =
2.030). Immunoreactivity scores were compared with
other groups and the difference was statistically significant
(proliferative lesions p < 0.002, carcinoma in situ p <
0.001, invasive carcinoma p < 0.001 and lymph node
metastasis p < 0.001). No significant difference was found
between fibroadenoma and non-proliferative lesions.
Table 1: Nm23 expression in spectrum of benign and malignant breast lesions
S.No Group No. of cases Mean score (Range) SD COV SE of mean
1 Non-proliferative lesions 13 7.150(4–9) 2.192 30.649 0.608
2 Fibroadenoma 7 7.860(4–9) 2.034 25.905 0.769
3. Proliferative lesions 13 5.461(2–9) 1.664 30.469 0.461
4 Carcinoma in situ 20 4.104(2–6) 1.651 40.271 0.369
5. Invasive carcinoma 23 2.871(0–6) 1.516 52.859 0.316
6. Lymph node metastasis 17 1.241(0–6) 1.855 150.170 0.449
SD-Standard deviation, COV-coefficient of variation, SE-Standard errorDiagnostic Pathology 2008, 3:23 http://www.diagnosticpathology.org/content/3/1/23
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Nm23 expression in proliferative breast lesions
This group includes moderate and florid hyperplasia(13
cases). Homogeneous moderate staining for nm23 was
noted in the hyperplastic areas with a score range of 2–
9(mean = 5.460, SD = 1.660) (Fig. 3). Scores varied signif-
icantly from scores of carcinoma in situ (p < 0.005), inva-
sive carcinoma(p < 0.001) and lymph node metastasis (p
< 0.001).
Nm23 expression in carcinoma in situ
Twenty cases of carcinoma in situ including one case of
lobular carcinoma in situ showing areas of atypical ductal
hyperplasia were studied. Weak to moderate immunore-
activity was noted in epithelial cells with score ranging
from 2–6(mean = 4.100, SD = 1.650). Carcinoma in situ
had greater nm23 expression than invasive carcinoma(p <
0.002) and lymph node metastasis (p < 0.001). No signif-
icant difference was observed in staining intensity of
comedo and non-comedo carcinoma in situ.
Nm23 expression in invasive carcinoma
This group includes 23 cases of invasive carcinoma. Most
of these showed extremely reduced nm23 expression in
tumour cells with score range of 0–6(mean = 2.870, SD =
1.510)(Fig. 4). The scores varied significantly when com-
pared with lymph node meatastasis (p < 0.001). Periduc-
tal elastosis was strongly stained. There was no difference
in staining intensity between ductal and lobular subtypes.
Nm23 expression in lymph node metastasis
Nm23 immunoreactivity was absent to weak in metastatic
tumour cells (Fig. 5). The score range was 0–6(mean =
1.240, SD = 1.850).
In this study there were 27 cases that showed spectrum of
lesions ranging from normal to metastatic disease. There
was a progressive down regulation of nm23 expression
with neoplastic transformation; so that scores of 9 in non-
proliferative breast disease decreased to 6 in carcinoma in-
situ, to 3 in invasive cancer and 0 in meatstatic cancers.
Photomicrograph showing moderate nm23 expression in  florid epithelial hyperplasia (Nm23 immunostain) Figure 3
Photomicrograph showing moderate nm23 expression in 
florid epithelial hyperplasia (Nm23 immunostain).
Photomicrograph showing strong nm23 expression in epithe- lial cells in fibrocystic change (Nm23 immunostain) Figure 1
Photomicrograph showing strong nm23 expression in epithe-
lial cells in fibrocystic change (Nm23 immunostain).
Photomicrograph showing strong nm23 expression in epithe- lial cells and a few stromal cells in fibroadenoma (Nm23  immunostain) Figure 2
Photomicrograph showing strong nm23 expression in epithe-
lial cells and a few stromal cells in fibroadenoma (Nm23 
immunostain).Diagnostic Pathology 2008, 3:23 http://www.diagnosticpathology.org/content/3/1/23
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Discussion
Oncogenes (C-erb2, C-myc, genes linked to 11q13,
tumour suppressor genes (retinoblastoma gene, p53) and
anti-metastatic gene (nm23) play important roles in
breast cancer progression [20]. Several investigators have
reported the probable inverse association of nm23 expres-
sion with disease prognosis and or metastasis [21]. Meta-
static process involves activation and down regulation of
multiple genes at each step of metastatic cascade. Though
there have been conflicting reports of increased nm23
expression in solid tumours (breast, colon, cervix,
melanoma) compared to the benign counterparts [22,23].
Recent studies, however, are more consistent with that of
nm23 functioning as a metastatic suppressor gene.
Royds et al [24] studied expression of nm23 in a variety of
breast lesions. All of their benign categories showed uni-
form epithelial cell staining. In in-situ category non-
comedo DCIS were positive whereas the comedo variants
were negative for the protein expression. They also found
that nm23 negativity was significantly associated with
worsening grade of ductal carcinoma and advancing
lymph node stage. They concluded that nm23 protein
expression decreases with advancing grade of breast
lesions and the negativity in comedo variant of DCIS is a
finding consistent with the fact that comedo histology is
known to have higher likelihood of becoming invasive.
Several other genetic alterations have been found to be
consistently associated with such tumour progression
apart from nm23. These include the FHIT gene located at
human chromosome 3p14.2, novel genes called mta1(in
rodents) or MTA1 (in humans), NES1, and the tumour
suppressor gene maspin [25-29]
In the present study, our aim was to evaluate the modula-
tion of nm23 expression in breast lesions as they progress
from "normal" to "invasive cancer" through varying stages
of "proliferative breast diseases". We detected the nm23
expression using immunohistochemistry and all the non-
proliferative lesions strongly expressed the protein.
Expression of nm23 was moderate in fibroadenoma, pro-
liferative breast diseases and in carcinoma in-situ. In inva-
sive carcinoma and metastatic diseases the nm23
expression was weak to absent. The difference in staining
in various subgroups was also statistically significant.
Thus our results show that there is down regulation of
nm23 expression with the progress of neoplastic transfor-
mation. These results implicate that lack of nm23 expres-
sion in early lesions may be predictive of progression to
invasive carcinoma. Though the findings in our study are
in concordance with that of Royds et al [24], we found no
difference in staining pattern between comedo versus
non-comedo variants of DCIS. Also no difference in stain-
ing pattern between the morphologic variants of carci-
noma (ductal/lobular) was detected in the present study.
Nm23 expression has been widely studied in various can-
cers and with their relation to staging and prognosis.
There are very few studies in literature which have system-
atically studied the expression of this protein in both
benign and malignant counterparts as spectrum. Our
study is one such attempt and the results implicate that
lack of nm23 expression in early lesions may be predictive
of progression to invasive carcinoma and thus could be
helpful in predicting the aggressiveness of the disease.
Photomicrograph showing absent nm23 expression in meta- static breast carcinoma Figure 5
Photomicrograph showing absent nm23 expression in meta-
static breast carcinoma. (Nm23 immunostain).
Photomicrograph showing weak to absent nm23 expression  in invasive ductal carcinoma cells (Nm23 immunostain) Figure 4
Photomicrograph showing weak to absent nm23 expression 
in invasive ductal carcinoma cells (Nm23 immunostain).Publish with BioMed Central    and   every 
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